|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00950 LEE'S PHARM
Nominal 
1.310 +0.030 (+2.344%) | 2024/12 - Final HKD(K$) | %Chg (Compare to Final) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | |
| Turnover | 1,399,969 | 32.946% | 1,053,034 | 1,233,148 | 1,266,157 | 1,216,716 |
| Cost of Sales | (646,614) | 28.879% | (501,723) | (462,393) | (459,873) | (435,650) |
| Gross Profit | 753,355 | 36.648% | 551,311 | 770,755 | 806,284 | 781,066 |
| 2024/12 - Final HKD(K$) | %Chg (Compare to Final) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | (90,284) | (1,180) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (839) | -3.563% | (870) | (1,104) | (3,495) | (11,414) | |
| Profit / (Loss) before Taxation | 98,113 | 218.704% | 30,785 | 67,861 | 1,969,366 | 134,037 | |
| Taxation | (29,501) | 172.250% | (10,836) | (22,026) | (9,482) | (55,503) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 24,487 | -- | (3,251) | 5,449 | 27,292 | 50,782 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 93,099 | 457.546% | 16,698 | 51,284 | 1,987,176 | 129,316 | |
| 2024/12 - Final HKD(K$) | %Chg (Compare to Final) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | |
| Net Finance Costs / (Income) | 12,057 | 16.335% | 10,364 | 5,202 | (190) | (2,600) |
| Depreciation & Amortisation | 147,731 | -1.184% | 149,501 | 152,499 | 146,867 | 127,504 |
| Directors' Emoluments | -- | -- | 32,861 | 10,264 | 92,625 | 48,115 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 15.810 | 456.690% | 2.840 | 8.710 | 337.580 | 21.990 |
| DPS (cts) | 4.500 | -- | 1.800 | 2.000 | 6.100 | 5.800 |
| Dividend Payout Ratio (%) | 28.463% | -- | 63.380% | 22.962% | 1.807% | 26.376% |
| Cash flow per share ($) | -- | -- | 0.187 | 0.482 | 0.358 | 0.372 |
| NBV per share ($) | 2.805 | -- | 3.463 | 3.268 | 4.186 | 3.655 |
| Remarks: | Real time quote last updated: 22/04/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K$) | HKD 93,099 |
| %Change | 457.546% |
| EPS / (LPS) | HKD 0.158 |
| NBV Per Share ($) | HKD 2.805 |